Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Whole Exome Sequencing Market Size

ID: MRFR//7291-CR | 164 Pages | Author: Kinjoll Dey| May 2020

Recent genomic research advances affect the WES market. As technology advances, researchers learn more about exomes, gene protein-coding regions, in many disorders. This makes WES a desired tool for comprehensive genomic analysis.
Growing awareness of genetic illnesses and disorders drives WES market expansion. Whole exome sequencing may discover genetic variations linked with uncommon and complicated illnesses, making it a popular diagnostic technique.
WES is widely used in oncology to detect somatic mutations in cancer genomes. Focus on precision medicine improves the industry since WES identifies genetic changes that drive targeted treatments and individualized cancer treatment regimens.
WES adoption is driven by sequencing technology cost reduction. WES becomes more affordable for research and clinical use as its cost per base pair lowers, boosting its market reach and use.
WES efficiency and accuracy improve with sequencing platform advancements. Next-generation sequencing (NGS) technologies enhance data quality, throughput, and turnaround times, impacting market choices.
WES is in demand due to the increasing expansion of precision medicine, which tailors therapy to genetic profiles. WES helps uncover genetic characteristics affecting treatment responses as healthcare becomes more individualized.
The WES market is affected by government genetic research and precision medicine financing. Research and partnerships promote WES incorporation into clinical practice and growth.
Industry, research, and healthcare groups collaborate to promote WES applications. Partnerships shape the industry by accelerating tool, bioinformatics, and analytical development.
WES's ability to discover genetic variations linked to illness susceptibility and treatment response affects market dynamics. WES helps doctors make educated patient care choices, promoting its adoption in healthcare.
WES data is more useful in clinical settings when integrated with EHRs. Healthcare providers' adoption of genomic information is affected by seamless interoperability.
WES demand is rising because to patient knowledge of genetic testing and its possible health benefits. Growing interest in proactive health management drives WES for early identification and prevention.
The WES market requires ethical and regulatory compliance. Responsible genetic data usage is regulated, impacting market entrance and business practices.
The WES market is affected by bioinformatics issues, especially genetic data interpretation. Bioinformatics tools and algorithms are needed to turn genetic data into practical insights, affecting market usability.

Global Whole Exome Sequencing Market Overview

Whole Exome Sequencing Market Size was valued at USD 1.5 Billion in 2022. The Whole Exome Sequencing market industry is projected to grow from USD 1.8 Billion in 2023 to USD 7.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.20% during the forecast period (2023 - 2032). Increased use of whole-exome sequencing technology for various applications and research & development are the key market drivers enhancing market growth.Whole Exome Sequencing Market

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Whole Exome Sequencing Market Trends

  • The growing use of whole-exome sequencing technology is driving the market growth

Market CAGR for whole exome sequencing technology's various applications is driven by the rising number of chronic and rare disorders, the increasing need for customized treatment, and rising next–generation sequencing.  A method for sequencing a genome’s exome and protein-coding genes is called exome sequencing and whole exome sequencing. In this process, the subset of DNA that codes for proteins or exons is chosen, and the exonic DNA is then sequenced utilizing high-throughput DNA sequencing techniques. Additionally, it offers a low-cost screening method for the detection of genetic diseases. It offers a less resource-intensive substitute for whole-genome sequencing in several applications, including drug development processes.

The growing demand for identifying uncommon diseases, expanding genomics and next-generation sequencing R&D, and rising demand for personalized treatment drive the whole exome sequencing market. For Instance In March 2022, As per British Medical Journal article, routine whole exome sequencing for detecting rare children's genetic illnesses is now available for highly selected kids. According to the report, next-generation sequencing enables the rapid and inexpensive sequencing of hundreds or thousands of genes. The advantages of exome sequencing are factors expected to grow the market.

Testing for the genomes of viruses that cause diseases, such as HIV, Cancer, and Covid-19, involves whole exome sequencing. The need for whole exome sequencing is fast expanding along with the prevalence of these disorders. For instance the World Health Organization (WHO) announced in July 2022 that there were 37.7 million HIV cases worldwide in 2021. Due to the rise in these illnesses and the increased demand for RNA sequencing, these genomic sequencing techniques offer information on genetic variations that can cause diseases. Thus, driving the Whole Exome Sequencing market revenue.

Whole Exome Sequencing Market Segment Insights

Whole Exome Sequencing Product Insights

The Whole Exome Sequencing market segmentation, based on product, includes kits, systems, and services. The system segment dominated the market, accounting for maximum market revenue. Next-Generation Sequencing (NGS) and data analysis services provided advanced bioinformatics visualization, allowing researchers to concentrate more on their work than laborious analysis operations. These sequence analysis services provide various services, such as library development from a wide range of samples, experimental planning, and downstream DNA sequence analysis.

Whole Exome Sequencing Technology Insights

The Whole Exome Sequencing market segmentation, based on technology, includes sequencing by synthesis (SBS) and ION semiconductor sequencing. The sequencing by synthesis (SBS) segment generated the most revenue. This technique eliminates mistakes and missed calls by repeating nucleotide strings. SBS technology offers long-insert paired-end reads for de novo sequencing, effective sequence assembly, and other uses, in addition to high-resolution genome sequencing, to short–insertpaired–end reads.

Figure 1 Whole Exome Sequencing Market, by Technology, 2022 & 2032 (USD Billion)Whole Exome Sequencing Market, by Technology, 2022 & 2032

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Whole Exome Sequencing Application Insights

The Whole Exome Sequencing market segmentation, based on application, includes diagnostics, drug discovery and developments, and agriculture and animal research. The drug discovery and development segment generated the maximum market revenue. Medical experts may create safer and more efficient treatment plans and drugs for various health disorders thanks to advancements in genetics. This drug discovery and development segment market is driven by the increase in the prevalence of different kinds of cancer, the affordability of personalized drug therapy, the high adoption in developed markets, and the development of novel drugs.

Whole Exome Sequencing End-User Insights

The Whole Exome Sequencing market segmentation, based on end-user, includes research centers and government institutes, hospitals and diagnostics centers, and pharmaceuticals & biotechnology companies. The research centers and government institutes category generated the most income. Research centers and government institutions have offered a clinical diagnosis of chronic diseases such as cardiovascular disorders, Alzheimer’s disease, cancer, and others. Moreover, R& D in the field of genomics is also supporting the segment's growth.

Whole Exome Sequencing Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Whole Exome Sequencing market will dominate this market, owing to an increase in hereditary and chronic diseases. In addition, the growing demand for targeted and personalized drugs will boost the market growth in this region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Whole Exome Sequencing market accounts for the second-largest market share due to the technological advancement in the field of genomics and the rise in R&D. Further, the German Whole Exome Sequencing market held the largest market share, and the UK Whole Exome Sequencing market the fastest growing market in the European region.

The Asia-Pacific Whole Exome Sequencing Market is expected to rise at the fastest CAGR from 2023 to 2032 due to the rising incidence of genetic abnormalities among people caused by increasing public knowledge of whole exome sequencing. Moreover, China’s Whole Exome Sequencing market held the largest market share, and the Indian Whole Exome Sequencing market was the fastest-growing market in the Asia-Pacific region.

Whole Exome Sequencing Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Whole Exome Sequencing market, grow even more. Market participants are also undertaking several strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The whole Exome Sequencing industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the  Whole Exome Sequencing industry to benefit clients and increase the market sector. In recent years, the Whole Exome Sequencing industry has offered some of the most significant medical advantages. Major players in the Whole Exome Sequencing market, including Illumina Inc. (US), BGI (China), Eurofins Scientific (Belgium), Thermo Fisher Scientific (US), Agilent Technologies Inc. (US), F.Hoffmann-La Roche Ltd. (Switzerland), GENEWIZ (US), Ambry Genetics (US), Macrogen Inc. (South Korea), Integragen SA (France), and others, are attempting to increase market demand by investing in research and development operations.

Illumina, Inc. (America) is a biotechnology company headquartered in San Diego, California, and it aids more than 140 countries. Illumina, founded on April 1, 1998, creates, produces, and sells integrated systems to study genetic variation and biological function. The business offers a selection of goods and services to cater to the markets for sequencing, genotyping and gene expression, and proteomics. For Instance in February 2023, as per Illumina Inc., the Broad Institute received the first NovaSeqX Plus Machine. The platform will assist parties wishing to access the company’s human whole genome product, lent genome/exome product, and sequencing service.

NanoString Technologies, Inc. is a publicly traded biotech company providing discovery and translation research solutions. The nCounter® Gene Expression System, the GeoMx® Digital Spatial Profiler, the CosMxTM Spatial Molecular Imager, and the AtoMX Spatial Informatics Platform are among the products made by NanoString. With the help of these four systems, researchers may see molecular interactions in three dimensions and understand how genes and proteins are expressed on a multi-genomic level about tissue shape. Products made by NanoString are based on a cutting-edge digital molecular barcoding technique developed at the Institute for Systems Biology by Dr. Leroy Hood. For Instance In May 2022, NanoString Tehnologies, Inc. released a cloud-based process that benefits users of the GeoMx Digital Spatial Profiler and Illumina NextSeq 1000 and NextSeq 2000 sequencing devices.

Key Companies in the Whole Exome Sequencing market include

  • Illumina Inc. (US)

  • BGI (China)

  • Eurofins Scientific (Belgium)

  • Thermo Fisher Scientific (US)

  • Agilent Technologies Inc. (US)

  • Hoffmann-La Roche Ltd. (Switzerland)


  • Ambry Genetics (US)

  • Macrogen Inc. (South Korea)

  • Integragen SA (France)

Whole Exome Sequencing Industry Developments

May 2022 Thermo Fisher Scientific and the Qatar Genome Program (QGP), a division of the Qatar Foundation (QF), come together for advancing genomic studies and therapeutic uses of predictive genomics in Qatar.

February 2021 Labcorp and OmniSeq, a CAP-accredited molecular diagnostic innovation of Rosewell Park Comprehensive Cancer Center, released the launch of OmniSeq INSIGHTsm, a thorough genomic and immunological profiling tissue-based test that incorporates Next Generation Sequencing (NGS) technology. OmniSeq is a CAP-accredited molecular diagnostic invention of Rosewell Park Comprehensive Cancer Center.

Whole Exome Sequencing Market Segmentation

Whole Exome Sequencing Products Outlook

  • Kits

  • Sequencer

  • Services

Whole Exome Sequencing Technology Outlook

  • Sequencing by Synthesis (SBS)

  • ION Semiconductor Sequencing

Whole Exome Sequencing Application Outlook

  • Diagnostics

  • Drug Discovery and Development

  • Agriculture and Animal Research

Whole Exome Sequencing End-User Outlook

  • Research Centers and Government Institutes

  • Hospitals and Diagnostics Centers

  • Pharmaceuticals & Biotechnology Companies

Whole Exome Sequencing Regional Outlook

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.